Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT04256473
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT04256473
-
- Other papers using this trial's data
- Safety and Efficacy of Dual Thrombolytic Therapy With Mutant Prourokinase and Small Bolus Alteplase for Ischemic Stroke: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT04256473. Randomized; single masking; primary purpose treatment. Start 2019-08-10 (actual); primary completion 2022-03-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke
- Acronym
- DUMAS
- Condition
- Ischemic Stroke
- Intervention (Drug)
- mutant pro-urokinase
- Intervention (Drug)
- Alteplase
- Lead sponsor
- Erasmus Medical Center
- Collaborator
- DUMAS is sponsored by an unrestricted grant from Thrombolytic Science International, paid to the institution.
Record details
- Record id
cardio:ct-nct04256473- Content hash
68393cd1e8ab1381a7797c729fd9f66cc9ec7080bdeeaa026907e7bb1774975f